Silo Pharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Silo Pharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +0% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+0% / -35%In 3 years sales changed by +0% while total assets changed by -35%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 81% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 84% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Silo Pharma, Inc. made a loss over the last year. Silo Pharma, Inc. owes $0.18 for every $1 it owns. Silo Pharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSilo Pharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.50The share price is 0.50 times Silo Pharma, Inc.'s book value per share, lower than 91% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Silo Pharma, Inc.'s shares at today's price (share price × number of shares), smaller than 97% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$5 MWhat Silo Pharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.38Net worth divided by the number of shares. The share price of $1.18 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-91.2%Silo Pharma, Inc. lost 91.2% of its shareholders' money over the last year, lower than 68% of Healthcare companies in United States.
Owes vs Owns
0.18×Silo Pharma, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Dividend yield
NoneSilo Pharma, Inc. does not currently pay a dividend.
Revenue growth
+0%Revenue rose 0% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Profit growth
LossSilo Pharma, Inc. made a loss in each of the last two years.
Profit margin
-5863.5%Silo Pharma, Inc. lost $5863 for every $100 of revenue.
Interest cover
Not coveredSilo Pharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Silo Pharma, Inc.: $2 M ÷ $5 M (30 Jun 2026) = 0.5.
What is Silo Pharma, Inc.'s return on equity?
Silo Pharma, Inc. lost 91.2% of its shareholders' money over the last year, lower than 68% of Healthcare companies in United States.
How much does Silo Pharma, Inc. owe compared with what it owns?
Silo Pharma, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Does Silo Pharma, Inc. pay a dividend?
No. Silo Pharma, Inc. does not currently pay a dividend.
Is Silo Pharma, Inc.'s revenue growing?
Revenue rose 0% in the year to Dec 2025, and grew 0% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.